Compare ZSTK & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZSTK | QNCX |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 17.5M |
| IPO Year | 2023 | 2019 |
| Metric | ZSTK | QNCX |
|---|---|---|
| Price | $4.84 | $29.55 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 17.2K |
| Earning Date | 05-12-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,676,000.00 | N/A |
| Revenue This Year | $15.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.32 | $0.08 |
| 52 Week High | $12.40 | $35.41 |
| Indicator | ZSTK | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 58.54 | 46.63 |
| Support Level | $4.76 | $0.82 |
| Resistance Level | $5.39 | $35.38 |
| Average True Range (ATR) | 0.98 | 2.07 |
| MACD | -0.13 | -1.04 |
| Stochastic Oscillator | 32.52 | 4.41 |
ZeroStack Corp is an AI focused asset management company. The company also operates a world-wide Commercial and wholesale business through its wholly owned subsidiary. ZeroStack is focused on providing exposure to decentralized AI through a concentrated digital asset approach structured to generate yield and fee-based income from staking validators, compute power technology companies, and complementary businesses within the ecosystem and across the wider AI landscape. The other segment commercial and wholesale (Phatebo and TruHC), which sell pharmaceutical products and mix of products across multiple categories including food and beverage, cannabis accessories and technology, personal care and wellness.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.